ArticleClinical cancer research : an official journal of the American Association for Cancer Research2013
Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer--response.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 1 synthesis or guideline pooled it.
- EGFR mutation status in non-small cell lung cancer receiving PD-1/PD-L1 inhibitors and its correlation with PD-L1 expression: a meta-analysis.Cancer immunology, immunotherapy : CII · 2022Pooled it
- Spatial interactions of immune cells as potential predictors to efficacy of toripalimab plus chemotherapy in locally advanced or metastatic pancreatic ductal adenocarcinoma: a phase Ib/II trial.Signal transduction and targeted therapy · 2024Trial
- Utility of [Cancer immunology, immunotherapy : CII · 2025Article
- PILRα on tumor cells interacts with the T cell surface protein CD99 to suppress antitumor immunity.Nature cancer · 2025Article
- Programmed Death Ligand-1 in Melanoma and Extracellular Vesicles Promotes Local and Regional Immune Suppression through M2-like Macrophage Polarization.The American journal of pathology · 2025Article
- Development of a Novel Anti-Siglec-15 Antibody for Tumor Immunotherapy.ImmunoTargets and therapy · 2025Article
- Sex-Related Differences in the Immune System Drive Differential Responses to Anti-PD-1 Immunotherapy.Biomolecules · 2024Article
- PD-L1-expressing natural killer cells predict favorable prognosis and response to PD-1/PD-L1 blockade in neuroblastoma.Oncoimmunology · 2024Article
- The critical roles of lnc-GLYATL2-2/PD-L1 axis in immune microenvironment and the clinical value of intracranial chordomas.American journal of cancer research · 2023Article
- Advancement of single-cell sequencing for clinical diagnosis and treatment of pancreatic cancer.Frontiers in medicine · 2023Review
- Screening and identification of an anti-PD-1 nanobody with antitumor activity.Bioscience reports · 2022Article
- Cancer Immunoediting in the Era of Immuno-oncology.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Article
- Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities.Nature reviews. Drug discovery · 2022Review
- Combination therapy for pancreatic cancer: anti-PD-(L)1-based strategy.Journal of experimental & clinical cancer research : CR · 2022Review
- Research status on immunotherapy trials of gastric cancer.World journal of clinical cases · 2021Review
- A human CD137×PD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade.Nature communications · 2021Article
- Systems biology informed neural networks (SBINN) predict response and novel combinations for PD-1 checkpoint blockade.Communications biology · 2021Article
- Defining muscle-invasive bladder cancer immunotypes by introducing tumor mutation burden, CD8+ T cells, and molecular subtypes.Hereditas · 2021Article
- The Prognostic Significance of PD1 and PDL1 Gene Expression in Lung Cancer: A Meta-Analysis.Frontiers in oncology · 2021Article
- Immune Check Point Inhibitors and Immune-Related Adverse Events in Small Cell Lung Cancer.Frontiers in oncology · 2021Review
3 more citing papers are in PubMed but not listed here.
Corrections and comments
- Comment on
- Comment on
Authors and funding
2 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.